Lipid profile screening in second-generation antipsychotic users: the gap between policy and practice

Bibliography

• National Center for Health Statistics: Health, United States, 2009, with Special Feature on Medical Technology. National Center for Health Statistics, MD, USA (2010).
   Google Scholar
• Newcomer JW, Hennekens CH: Severe mental illness and risk of cardiovascular disease. JAMA 298(15), 1794–1796 (2007).
   Google Scholar
• Miller BJ, Paschall CB III, Svendsen DP: Mortality and medical comorbidity among patients with serious mental illness. Psychiatr. Serv. 57(10), 1482–1487 (2006).
   Google Scholar
• Newcomer JW: Medical risk in patients with bipolar disorder and schizophrenia. J. Clin. Psychiatry 67(Suppl. 9), 25–30; discussion 36–42 (2006).
   Google Scholar
• Felker B, Yazel JJ, Short D: Mortality and medical comorbidity among psychiatric patients: a review. Psychiatr. Serv. 47(12), 1356–1363 (1996).
   Google Scholar
• Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM: Quality of medical care and excess mortality in older patients with mental disorders. Arch. Gen. Psychiatry 58(6), 565–572 (2010).
   Google Scholar
• Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 28(7), 1769–1778 (2005).
   Google Scholar
• McEvoy JP, Meyer JM, Goff DC et al.: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80(1), 19–32 (2005).
   Google Scholar
• Sacks FM: Metabolic syndrome: epidemiology and consequences. J. Clin. Psychiatry 65(Suppl. 18), 3–12 (2004).
   Google Scholar
• Bell RC, Farmer S, Ries R, Srebnik D: Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatr. Serv. 60(12), 1686–1689 (2009).
   Google Scholar
• Hartung DM, Wisdom JP, Pollack DA et al.: Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. J. Clin. Psychiatry 69(10), 1540–1547 (2008).
   Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 373(9657), 31–41 (2009).
   Google Scholar
• Allison DB, Mentore JL, Heo M et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156(11), 1686–1696 (1999).
   Google Scholar
• Newcomer JW, Haupt DW: The metabolic effects of antipsychotic medications. Can. J. Psychiatry 51(8), 480–491 (2006).
   Google Scholar
• Koller E, Schneider B, Bennett K, Dubitsky G: Clozapine-associated diabetes. Am. J. Med. 111(9), 716–723 (2001).
   Google Scholar
• Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 70(1), 1–17 (2004).
   Google Scholar
• Birkenaes AB, Birkeland KI, Engh JA et al.: Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J. Clin. Psychopharmacol. 28(2), 132–137 (2008).
   Google Scholar
• Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl. 1), 1–93 (2005).
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209–1223 (2005).
   Google Scholar
• Koro CE, Fedder DO, L’Italien GJ et al.: An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch. Gen. Psychiatry 59(11), 1021–1026 (2002).
   Google Scholar
• Kane JM, Osuntokun O, Kryzhanovskaya LA et al.: A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J. Clin. Psychiatry 70(4), 572–581 (2009).
   Google Scholar
• Nussbaum A, Stroup TS: Paliperidone for schizophrenia. Cochrane Database Syst Rev. (2), CD006369 (2008).
   Google Scholar
• Scott LJ: Iloperidone: in schizophrenia. CNS Drugs 23(10), 867–880 (2009).
   Google Scholar
• Fanapt®, package insert. Vanda Pharmaceuticals Inc., MD, USA (2009).
   Google Scholar
• Weber J, McCormack PL: Asenapine. CNS Drugs 23(9), 781–792 (2009).
   Google Scholar
• American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; and North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2), 596–601 (2004).
   Google Scholar
• Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW: Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am. J. Psychiatry 166(3), 345–353 (2009).
   Google Scholar
• Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B: Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32(6), 1037–1042 (2009).
   Google Scholar
• Morrato EH, Druss B, Hartung DM et al.: Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch. Gen. Psychiatry 67(1), 17–24 (2010).
   Google Scholar
• Morrato EH, Newcomer JW, Allen RR, Valuck RJ: Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J. Clin. Psychiatry 69(2), 316–322 (2008).
   Google Scholar
• Hsu C, Ried LD, Bengtson MA, Garman PM, McConkey JR, Rahnavard F: Metabolic monitoring in veterans with schizophreniarelated disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. J. Am. Pharm. Assoc. 48(3), 393–400 (2008).
   Google Scholar
• Grundy SM: Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am. J. Cardiol. 90(8 Suppl. 1), 11–21 (2002).
   Google Scholar
• Nasrallah HA, Meyer JM, Goff DC et al.: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 86(1–3), 15–22 (2006).
   Google Scholar
• Newcomer JW, Nasrallah HA, Loebel AD: The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J. Clin. Psychopharmacol. 24(5 Suppl. 1), S1–S6 (2004).
   Google Scholar
• Ketter TA, Haupt DW: Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Curr Med Res Opin. 22(12), 2345–2353 (2006).
   Google Scholar
• Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM: Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophr. Res. 79(2–3), 281–288 (2005).
   Google Scholar
• Doey T, Handelman K, Seabrook JA, Steele M: Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can. J. Psychiatry 52(6), 363–368 (2007).
   Google Scholar
• Walter G, DeLaroche A, Soh N et al.: Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australas. Psychiatry. 16(4), 253–262 (2008).
   Google Scholar
• Morrato EH, Druss B, Hartung DM et al.: Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch. Gen. Psychiatry 67(1), 17–24 (2010).
   Google Scholar
• Bender E: Psychiatrists, patients disagree about extent of communication. Psych. News 43(6), 14 (2008).
   Google Scholar
• Fenton WS, Chavez MR: Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am. J. Psychiatry 163(10), 1697–1704; quiz 1858–1699 (2006).
   Google Scholar
• Motsinger CD, Perron GA, Lacy TJ: Use of atypical antipsychotic drugs in patients with dementia. Am. Fam. Physician 67(11), 2335–2340 (2003).
   Google Scholar
• Barnes TRE, Paton C, Hancock E, Cavanagh M-R, Taylor D, Lelliott P: Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr. Scand. 118(1), 26–33 (2008).
   Google Scholar